Pharmacovigilance: A Worldwide Master Key for Drug Safety Monitoring
Pharmacovigilance is like a sunshade to describe the processes for monitoring and evaluating ADRs and it is a key component of effective drug regulation systems, clinical practice and public health programmes. The number of Adverse Drug Reactions (ADRs) reported resulted in an increase in the volume of data handled, and to understand the pharmacovigilance, a high level of expertise is required to rapidly detect drug risks as well as to defend the product against an inappropriate removal.
Drug Safety and Pharmacovigilance: Effective Drug Safety Reporting and Surveillance
Download PDF Brochure: https://bit.ly/Pharmacovigilance-Drugs-Safety
Increasing cases of adverse drug reactions and increasing consumption of drugs across the globe are expected to fuel the growth of the pharmacovigilance in coming future. Moreover, shift in outsourcing of various activities among pharmaceutical and life science sector is anticipated to offer significant growth opportunities in the sector.
The current global network of pharmacovigilance centers, coordinated by the Uppsala Monitoring Centre, would be strengthened by an independent system of review. This would consider litigious and important drug safety issues that have the potential to affect public health adversely beyond national boundaries. Recently, pharmacovigilance has been confined, mainly to detect adverse drug events that were previously either unknown or poorly understood.
Pharmacovigilance is an important and integral part of clinical research and these days it is growing in many countries. Today many pharmacovigilance centers are working for drug safety monitoring in this global pitch, however, at the turn of the millennium pharmacovigilance faces major challenges in aspect of better safety and monitoring of drugs. In this review we will discuss about drug safety, worldwide pharmacovigilance centers and their role, benefits and challenges of pharmacovigilance and its future consideration in healthcare sectors.